Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Six-week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.

ClinicalTrials.gov ID: NCT00282464

Public ClinicalTrials.gov record NCT00282464. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 1, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a 6-week trial that evaluates the efficacy and safety of Geodon (ziprasidone) in outpatient subjects ages 18 and older with Bipolar Disorder type I, depressed. Subjects are required to undergo a washout period of at least 7 days of any prior med.

Study identification

NCT ID
NCT00282464
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
392 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2006
Primary completion
Feb 29, 2008
Completion
Feb 29, 2008
Last update posted
Mar 28, 2021

2006 – 2008

United States locations

U.S. sites
43
U.S. states
22
U.S. cities
42
Facility City State ZIP Site status
Pfizer Investigational Site Dothan Alabama 36303
Pfizer Investigational Site Little Rock Arkansas 77205
Pfizer Investigational Site Anaheim California 92804
Pfizer Investigational Site Cerritos California 90703
Pfizer Investigational Site Chula Vista California 91910
Pfizer Investigational Site Escondido California 92025
Pfizer Investigational Site Los Angeles California 90027-5302
Pfizer Investigational Site Riverside California 92506
Pfizer Investigational Site San Diego California 92126
Pfizer Investigational Site Santa Ana California 92705
Pfizer Investigational Site Denver Colorado 80220
Pfizer Investigational Site Darien Connecticut 06820
Pfizer Investigational Site Boca Raton Florida 33432
Pfizer Investigational Site Bradenton Florida 34208
Pfizer Investigational Site Jacksonville Florida 32256-2006
Pfizer Investigational Site Melbourne Florida 32901
Pfizer Investigational Site Orange City Florida 32763
Pfizer Investigational Site Tampa Florida 33613
Pfizer Investigational Site Atlanta Georgia 30328
Pfizer Investigational Site Marietta Georgia 30060
Pfizer Investigational Site Eagle Idaho 83616
Pfizer Investigational Site Granite City Illinois 62040-4749
Pfizer Investigational Site Terre Haute Indiana 47802
Pfizer Investigational Site Glen Burnie Maryland 21061
Pfizer Investigational Site Towson Maryland 21204
Pfizer Investigational Site Rochester Minnesota 55905
Pfizer Investigational Site St Louis Missouri 63118
Pfizer Investigational Site Princeton New Jersey 08540
Pfizer Investigational Site Brooklyn New York 11223
Pfizer Investigational Site Brooklyn New York 11235
Pfizer Investigational Site New York New York 10003
Pfizer Investigational Site Olean New York 14760
Pfizer Investigational Site Durham North Carolina 27704
Pfizer Investigational Site Raleigh North Carolina 27609
Pfizer Investigational Site Toledo Ohio 43623
Pfizer Investigational Site Tulsa Oklahoma 74135
Pfizer Investigational Site Philadelphia Pennsylvania 19149
Pfizer Investigational Site Scranton Pennsylvania 18503
Pfizer Investigational Site Lincoln Rhode Island 02865
Pfizer Investigational Site Dallas Texas 75231
Pfizer Investigational Site Houston Texas 77007
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Charlottesville Virginia 22903-4895

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00282464, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 28, 2021 · Synced Sep 1, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00282464 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →